Form 4: Kairos Pharma VP R&D Granted 152,672 RSUs

Kairos Pharma's VP of Research and Development, Murali Ramachandran, was granted 152,672 restricted stock units under the company's 2023 Equity Incentive Plan.

Summary

• Murali Ramachandran, VP of Research and Development at Kairos Pharma, LTD. (KAPA), acquired 152,672 restricted stock units (RSUs).
• The transaction occurred on October 8, 2025, with a price of $0.00 per unit.
• These RSUs were issued under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan.
• The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date, which is October 8, 2026.
• Following this transaction, Mr. Ramachandran beneficially owns 299,529 securities, comprising 142,191 shares of common stock and 157,338 RSUs still subject to vesting.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: The grant of RSUs to a key R&D executive is generally positive, indicating retention and alignment of interests. It's a routine compensation event, not a major market mover, but reflects ongoing executive commitment.

Positives

• The grant of restricted stock units to a key executive, the VP of Research and Development, indicates management retention and alignment of interests with shareholders.
• The use of a Rule 10b5-1(c) plan demonstrates a pre-planned and compliant approach to equity transactions.

Future Outlook

NA

Industry Context

The grant of equity compensation like RSUs is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key scientific and executive talent, aligning their long-term interests with company performance and shareholder value creation.

Comparison to Industry Standards

• Equity grants to R&D leadership are common across the biotech sector, comparable to practices at companies like Moderna or BioNTech, where significant portions of executive compensation are tied to stock performance and vesting schedules to encourage long-term commitment and innovation.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive interests with long-term company performance.
• Employees: Standard compensation practice for key personnel, potentially boosting morale and retention within the R&D team.

Next Steps

• The 152,672 restricted stock units are scheduled to vest in full on October 8, 2026.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a standard compensation practice and does not provide new fundamental information to warrant a change in investment recommendation. It reinforces management's alignment with shareholder interests but doesn't signal a significant catalyst for immediate stock price movement.

Keywords

Kairos Pharma, KAPA, Murali Ramachandran, Restricted Stock Units, RSUs, Equity Incentive Plan, Insider Transaction, Form 4, Executive Compensation, Biotechnology, Pharmaceuticals